Prelude Therapeutics (PRLD) Treasury Shares (2019 - 2026)

Prelude Therapeutics has disclosed Treasury Shares across 8 years of filings, most recently posting $439080.0 for Q1 2026.

• Treasury Shares for Q1 2026 came in at $439080.0, up 14.08% year-over-year; the trailing twelve-month figure through Mar 2026 was $439080.0 (up 14.08% YoY), and the FY2025 annual result was $220500.0, up 292.0% from the prior year.
• Treasury Shares came in at $439080.0 for Q1 2026 at Prelude Therapeutics, up from $220500.0 in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $514641.0 in Q1 2022 to a low of $56250.0 in Q4 2024.
• The 5-year median for Treasury Shares is $165000.0 (2022), against an average of $206167.4.
• Across the five-year window, Treasury Shares slumped 79.81% in 2022 and jumped 313.29% in 2025, its largest moves.
• Prelude Therapeutics' Treasury Shares stood at $165000.0 in 2022, then sank by 37.12% to $103750.0 in 2023, then plunged by 45.78% to $56250.0 in 2024, then soared by 292.0% to $220500.0 in 2025, then surged by 99.13% to $439080.0 in 2026.
• The last three Treasury Shares figures came in at $439080.0 (Q1 2026), $220500.0 (Q4 2025), and $292375.0 (Q3 2025), per Business Quant data.